The random effects consisted of patient-specific intercepts and slopes as well as a residual variance. The variance of the random intercept, D(1,1), represented the degree of variability of patients’ cognitive impairment at baseline, while the variance of the random slope, D(2,2), indicated whether response to management over time was similar (small) or variable (large) between patients. The covariance (correlation) between the patient-specific intercept and slope indicated Venetoclax manufacturer whether the evolution of patients’ cognitive impairment over time was related to their
condition at baseline. Higher order (quadratic and cubic) models were considered at both the fixed- and random-effects level and Akaike’s information criteria (AIC) indicated that the linear model was acceptable (Table 3) [30]. Fig. 2 LOESS line plots of cognitive outcomes
over time by randomly selected Dabrafenib clinical trial patients and diagnosis groups: a patient-level evolution of MMSE, b average evolution of MMSE by diagnosis group, c patient-level evolution of MoCA, and d average evolution of MoCA by diagnosis group. AD Alzheimer’s disease, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment, svCVD small vessel cerebrovascular disease Table 3 Univariable and multivariable analyses of cognitive outcomes based on MMSE and MoCA Models MMSE MoCA Estimate (SD) p value Estimate (SD) p value Base model Intercept
20.33 (0.45) <0.0001 19.83 (0.51) <0.0001 Pure AD 2.36 (1.03) 0.0226 1.85 (1.12) 0.0999 FDur (months) −0.04 (0.01) 0.0101 −0.04 (0.02) 0.0168 PureAD × FDur −0.03 (0.03) 0.2160 −0.02 (0.03) 0.5409 D11 24.60 (3.07) <0.0001 21.53 (3.52) <0.0001 D12 0.12 (0.07) 0.0977 −0.02 (0.10) 0.8532 D22 0.01 (0.00) <0.0001 0.01 (0.00) 0.0042 Residual variance 5.74 (0.33) <0.0001 5.52 (0.45) <0.0001 Univariable models Age −0.08 (0.05) 0.1227 −0.08 (0.06) 0.1318 Female −2.51 (0.80) 0.0018 −1.99 (0.85) 0.0206 Chinese −1.13 (0.99) 0.2505 0.19 (1.05) 0.8597 Years of education 0.39 (0.08) <.0001 0.21 (0.10) 0.0294 Diabetes mellitus −0.67 (0.91) 0.4606 −0.62 (1.02) 0.5426 Hypertension −0.09 (0.83) 0.9153 0.03 (0.90) 0.9720 Hyperlipidemia selleck kinase inhibitor 0.63 (0.83) 0.4460 0.99 (0.92) 0.2847 Medicationsa Donepezil 0.06 (0.47) 0.9018 −0.27 (0.66) 0.6877 Galantamine 0.08 (0.67) 0.9096 0.93 (0.98) 0.3415 Memantine −1.58 (0.71) 0.0266 −0.88 (1.20) 0.4624 Rivastigmine – – – Duration of treatment 0.01 (0.01) 0.4651 −0.01 (0.02) 0.5022 Baseline MoCA|MMSE 0.68 (0.05) <0.0001 0.84 (0.06) <0.0001 Baseline GDS 0.08 (0.18) 0.6693 0.03 (0.21) 0.886 Multivariable models Intercept 18.04 (0.63) <0.0001 18.33 (0.84) <0.0001 Pure AD 1.48 (1.04) 0.1561 1.64 (1.11) 0.1396 FDur (months) −0.04 (0.01) 0.0069 −0.04 (0.02) 0.0189 Pure AD × FDur −0.03 (0.03) 0.2461 −0.02 (0.03) 0.